This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug
by Zacks Equity Research
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.
Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA
by Zacks Equity Research
The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.
Align (ALGN) Hurt by Dental Practice Closures, FX Headwind
by Zacks Equity Research
Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
by Zacks Equity Research
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
by Zacks Equity Research
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
Here's Why Investors Should Retain Chemed (CHE) Stock Now
by Zacks Equity Research
Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
by Zacks Equity Research
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
by Zacks Equity Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the second half of 2022.
LabCorp (LH) Rides on Innovations Amid Cost Constraints
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
by Zacks Equity Research
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
by Zacks Equity Research
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
by Zacks Equity Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays
by Zacks Equity Research
Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
by Zacks Equity Research
Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod
by Zacks Equity Research
Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.
Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
by Zacks Equity Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite
by Zacks Equity Research
PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.
Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation
by Zacks Equity Research
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
by Zacks Equity Research
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
by Zacks Equity Research
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.